Pre-market analysis
1)Nifty closed at 11896.45 down by 0.35% and banknifty closed at 24484.15 down 0.61%. 2)Global markets closed positive yesterday. |
3)Today, US and Europe futures are trading flat and asian markets are trading mixed and sgx nifty future is trading at 11909.80 up 0.09%
4) We may open flat or gap up of around 30-50 pts and follow global futures as the day progresses.
5)Support and resistance for nifty and banknifty
6)Nifty option pain is at 11700 and banknifty option pain is at 24000.
7)Nifty may trade between 11500 and 12000 and banknifty may trade between 23500 and 25000 for this week.this are very strong support and resistances as per oi chain.
8)Results today
Nestle India
Tech Mahindra
JSW Steel
Yes Bank
ICICI Lombard General Insurance
Heidelberg Cement
Persistent Systems
IDBI Bank
Sudarshan Chemicals
Mahindra EPC
Huhtamaki PPL
Aarti Drugs
Alphageo
Atul Ltd
Rane Engine Valve
Supreme Petro
9)Stocks in news
KIRLOSKAR BROTHERS
Company says that no fraud was found in the SEBI order against promoters Sanjay Kirloskar and Pratima Kirloskar
EQUITAS HOLDINGS
Arm Equitas SFB – IPO Closed Yesterday
Very Muted Response
Overall Subscribed = 1.95x
HNI’s Only 0.22x
Pfizer
Pfizer said it could be ready to apply for emergency-use authorization of its COVID-19 vaccine by late November, hope it receives positive efficacy and safety data from human trials, first time any leading Vaccine developer provided such a specific timeline
FDA approves Gilead's Remdesivir as first COVID-19 treatment
Stocks in focus
CIPLA
JUBILANT LIFE
CADILA HEALTH
Dr. REDDY'S
HDFC AMC
Q2-QoQ = Weak
Equity Market Share @ 13.6% Vs 14.3% QoQ (Down 70 Bps)
Debt Market Share @ 13.6% Vs 12.9% QoQ (Up 70 Bps)
Number of individual accounts declined to 9.21 Mn from 9.35 Mn QoQ
Revenue Up 11%; Profit Up 12%
L&T FINANCE
Q2-Weak
Loan growth is the lowest ever – the slide continues – leads to NII Missing Estimates
Disbursals continue to remain weak for 9 qtrs in a row
AUM growth is the weakest ever due to 9qtrs of weak disbursals
Collection efficiency is at 90% in Sept’20
ALEMBIC PHARMA
Q2-YoY = GOOD
Much Better Than Brokerage Estimates
Revenues +17%; EBITDA +28%
OPM @ 30.4% Vs 27.9% (Up 250 Bps Vs Exp of 130 Bps Improvement)
PAT Up 30%
Company says 5+ products planned to be launched in Q3
MPHASIS
Q2-QoQ = GOOD
Good Quarter, Revenue Beat, Margins Inline
CC Rev up 6% QoQ , up 6.7% YoY
Company reports highest ever deal wins in ths qtr at $ 360 Million
EBIT % at 16.1% vs 15.66% - Up 44 Bps
PAT up 8.7% at Rs 299.2 cr vs Rs 275.1 cr
BIOCON
Q2-YoY = WEAK
Weak Numbers, Lower Than Expectations
Revenue +12% (Expected Up 18%)
EBITDA Down 3% (Expected Up 20%)
Margins @ 22.4% Vs 25.8% (Down 340 Bps Vs Exp of Up 30 Bos)
PAT Down 24% @ Rs 195 Crores (Exp Down 11%)
Concall @ 9:00 AM Today
10)F&O BAN
New in Ban: None
Still in Ban: BHEL, CANBK, MINDTREE, NATIONALUM, PNB
Out of Ban: IBULHSGFIN, IDEA
11)Happy Trading
12)Follow our telegram channel 'Optionstraders' for calls on equity and options.
Comments
Post a Comment